Makale detayı · 2016
Evaluation of Paraoxonase Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical Atypical and Combined Antipsychotic Treatment
Clinical Psychopharmacology and Neuroscience
- Yıl
- 2016
- ISSN
1738-1088- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
İngilizce (OpenAlex)
OBJECTIVE: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls. METHODS: We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined antipsychotics) and 43 healthy controls. RESULTS: =0.005). PON1 activity was similar in all groups. CONCLUSION: Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.
Konular
- Paraoxonase enzyme and polymorphisms
- Tryptophan and brain disorders
- Enzyme function and inhibition
Birincil konu Paraoxonase enzyme and polymorphisms